To recover your password please fill in your email address
Please fill in below form to create an account with us
CONTROL NETs is two non-comparative parallel group phase II randomised open label trials of PRRT and CAPTEM in two cohorts of NET patients. Cohort A is comprised of patients with low to intermediate grade pancreatic neuroendocrine tumours (pNETs) randomised to receive PRRT + CAPTEM or CAPTEM alone. Cohort B is comprised of patients with low to intermediate grade midgut neuroendocrine tumours (mNETs) randomised to receive PRRT + CAPTEM or PRRT alone.
See ANZCTR for full trial details >
|
Trial Summary: |
To determine the relative activity of capecitabine and temozolomide (CAPTEM)/ 177Lu-Octreotate peptide receptor radionuclide therapy (PRRT) in biopsy-proven, low to intermediate grade, unresectable, metastatic 68Ga-octreotate PET-avid pancreatic and midgut Neuroendocrine Tumours (NETs). To inform future comparative phase III randomised controlled trials (RCTs) to determine the optimal therapies in pancreatic and midgut NETs. |
|
Supported By: |
Unicorn Foundation; AGITG; NHMRC CTC |
|
Eligibility: |
Adult patients with advanced, unresectable low or intermediate grade (Ki-67) |
|
Registration ID: |
NCT02358356 |
|
Participation: |
ANZ |
|
Australian Lead Group: |
AGITG |
|
Status: |
In follow-up |
|
Activation Date: |
|
|
Chairs: |
Nick Pavlakis and J Harvey Turner |
|
Contact: |